KLDO Stock Overview
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Kaleido Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.03 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -50.00% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Kaleido Biosciences EPS misses by $0.01
May 04Is Kaleido Biosciences, Inc. (NASDAQ:KLDO) Popular Amongst Insiders?
Feb 09
Kaleido Biosciences announces $50M proposed public offering
Feb 03Kaleido Bio's KB109 shows benefit in COVID-19 study
Jan 14Kaleido concludes enrollment in KB109 study in COVID-19
Jan 04Are Insiders Buying Kaleido Biosciences, Inc. (NASDAQ:KLDO) Stock?
Dec 14Shareholder Returns
| KLDO | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 0.08% | 1.2% |
| 1Y | -50.0% | 13.2% | 24.9% |
Return vs Industry: KLDO underperformed the US Pharmaceuticals industry which returned 13.9% over the past year.
Return vs Market: KLDO underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| KLDO volatility | |
|---|---|
| KLDO Average Weekly Movement | 3,458.3% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: KLDO's share price has been volatile over the past 3 months.
Volatility Over Time: KLDO's weekly volatility has decreased from 6409% to 3458% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | n/a | kaleido.com |
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases.
Kaleido Biosciences, Inc. Fundamentals Summary
| KLDO fundamental statistics | |
|---|---|
| Market cap | US$4.26k |
| Earnings (TTM) | -US$90.29m |
| Revenue (TTM) | US$1.10m |
0.0x
P/S Ratio0.0x
P/E RatioIs KLDO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KLDO income statement (TTM) | |
|---|---|
| Revenue | US$1.10m |
| Cost of Revenue | US$67.80m |
| Gross Profit | -US$66.70m |
| Other Expenses | US$23.59m |
| Earnings | -US$90.29m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did KLDO perform over the long term?
See historical performance and comparison